RH
Roche Holding AG
RHHBF · OTC
$453.84 +1.99% (+$8.88)
1M -7.30%
Market Cap CHF 291.1B
P/E Ratio 22.59x
Div. Yield 2.79%
ROE 40.66%
Bulios Fair Price
$405.59
10.6% downside
Current Price
$453.84
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RHHBF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
53 /100
Fair P/E 22.59x
PEG 0.41x
EV/EBITDA 14.11x
Growth
27 /100
Declining EPS growth 1.45%
Book val. growth 6.51%
Rev. growth 0.92%
Profitability
100 /100
Strong Gross margin 72.94%
FCF margin 22.89%
Net margin 20.94%
Quality
88 /100
Excellent ROIC 17.22%
Asset turnover 0.61x
ROE 40.66%
Debt
73 /100
Low Debt/Equity 1.02x
Net debt/EBITDA 1.27x
Current ratio 1.38x
Stability
68 /100
Stable Beta 0.35x
Profitable years 6
Rev. volatility 3.88%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RHHBF
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Thomas Schinecker
Employees
103,249
Headquarters
Basel
Upcoming events
04 FEB
Earnings
Upcoming earnings report